Eli Lilly’s orforglipron outshines oral semaglutide in landmark diabetes trial

The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints

Novartis completes $12 billion acquisition of Avidity Biosciences

The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity

Novartis’ remibrutinib bags positive CHMP opinion for chronic urticaria

The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines

Novo Nordisk slashes prices of Wegovy & Ozempic by up to 50%

The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients

Star Health & Allied Insurance rolls out 32 free primary care clinics across 9 states

The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives

Novo Nordisk & Vivtex team up to revolutionize oral hiologics

Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk

Merck Animal Health gets FDA nod for groundbreaking dog allergy drug NUMELVI

CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC

Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity

Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ

The innovative eyedrop targets inflammation and pain following ocular surgery

BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders

The announcement follows a record-setting $1.2 million accelerated LineaDNA order